For a post-menopausal woman with a pT1c node negative HER2 positive breast cancer, does ER status influence your choice of adjuvant paclitaxel/trastuzumab versus docetaxel/carboplatin/trastuzumab?
This is a patient with a 1.8 cm node-negative HER2-positive tumor that is grade 3, high Ki67, and ER-positive.
Community PollStarted
What adjuvant HER2 directed therapy would you offer for a patient with pT1cN0 HER2+ breast cancer who went to surgery first?
105 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center
Answered on
Data from pivotal trials addressing adjuvant therapy options for HER2 positive cancers, like BCIRG 006 and APT, doesn't support treating ER positive, HER2 positive cancers any differently than ER negative, HER2 positive cancers.
BCIRG 006 that showed TCH regimen to be as good as ACT-H (and superior t...
Join for free or sign in to see the full answer